Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial)

Inclusion criteria

• Age 18-80 years old.
• GCS scores ≤8 upon admission.
• ROSC ≥30min.
• Signed the informed consent form.

Exclusion criteria

• Cardiac arrest due to irreversible causes such as trauma, poisoning, etc.
• Cardiac arrest due to end-stage conditions such as advanced cancer.
• Persistent cardiogenic shock that is unreversed (defined as a systolic blood pressure persistently <90mmHg despite treatment with fluid resuscitation, vasopressor agents, and inotropic medications).
• Presence of pre-existing cerebrovascular disease prior to cardiac arrest or confirmed intracranial hemorrhage by CT scan following admission.
• Pre-existing CPC scores of 3-5 prior to cardiac arrest.
• Prior use of NBP or any medication containing NBP before cardiac arrest.
• Presence of severe hepatic or renal dysfunction before cardiac arrest (defined as ≥3× upper limit of normal alanine transaminase or ≥2× upper limit of normal creatinine).
• Bradycardia or sick sinus syndrome occurs after ROSC.
• History of prior drug or food allergies, or known allergies to the medication components used in this study.
• Existence of treatment limitations (patient or their legal representative refusing advanced life support treatment, including mechanical ventilation, chest compressions, targeted temperature management, etc.).
• Presence of severe bleeding tendency upon admission.
• Body temperature <30℃ upon admission.
• Pregnant or lactating women, or reproductive-age females with elevated serum hCG levels.
• Other conditions deemed unsuitable for this trial by the principal investigator.